AP
CBAY

AtonRa Partners’s Cymabay Therapeutics CBAY Stock Holding History

AtonRa Partners’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-111,525
Closed -$506K – 119
2021
Q1 		$506K Buy
111,525
+23,544
+27% +$127K 0.23% 106
2020
Q4 		$505K Buy
+87,981
New +$666K 0.25% 102

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

AtonRa Partners's CBAY Position: Q2 2021 in Review

AtonRa Partners sold out of Cymabay Therapeutics (CBAY) in Q2 2021, closing a stake of 111,525 shares — an estimated $506K sold.

AtonRa Partners first reported a position in CBAY in Q4 2020 and held it in 2 quarters. The position peaked at $506K in Q1 2021. 113 funds tracked by Wall St. Rank hold CBAY as of Q2 2021.

  • AtonRa Partners reported no remaining Cymabay Therapeutics position as of Q2 2021 after selling out during the quarter.
  • AtonRa Partners sold 111,525 Cymabay Therapeutics shares in Q2 2021, an estimated $506K.
  • AtonRa Partners first reported a position in Cymabay Therapeutics in Q4 2020 and held it in 2 quarters.
  • AtonRa Partners's Cymabay Therapeutics position peaked at $506K in Q1 2021.
  • 113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2021.

Based on AtonRa Partners's 13F filing for Q2 2021, filed 12 Aug 2021.